Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials

@article{Zhan2018PreventiveUO,
  title={Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials},
  author={Tao Zhan and Muhammad Daniyal and J Li and Y Mao},
  journal={Herz},
  year={2018},
  pages={1-14}
}
BackgroundClinical or subclinical cardiotoxicity is a concern for cancer patients receiving anthracycline-based chemotherapy. Carvedilol is promising for preventing anthracycline-induced cardiotoxicity (AIC). This review appraised the preventive effects of carvedilol against AIC based on randomized controlled trials (RCTs).MethodsThe Cochrane Collaboration Central Register of Controlled Trials, PubMed, and Embase databases were searched from inception to March 27, 2018. RCTs using carvedilol… CONTINUE READING
4
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 61 REFERENCES

Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2016
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Preventive role of carvedilol in adriamycin-induced cardiomyopathy

  • The Indian journal of medical research
  • 2016
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

  • Journal of the American College of Cardiology
  • 2006
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL